Skip to main content
. 2020 Jun 10;40(8):1800–1811. doi: 10.1111/liv.14533

Table 4.

Some considerations when choosing second‐ or third‐line systemic treatment for patients with advanced HCC in clinical practice

Second‐line treatment Third‐line treatment
Sorafenib‐intolerant patients Patients with low AFP
Regorafenib No Yes No
Cabozantinib Yes Yes Yes
Ramuciramab Yes No No

Abbreviations: AFP, alpha‐fetoprotein; HCC, hepatocellular carcinoma.